# Peter Schmid

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/peter-schmid/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,575 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 62 |
| i10-index | 152 |
| OpenAlex ID | https://openalex.org/A5111951182 |
| Works | 375 |

## Researcher papers

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple/)
- [Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial](https://scholariq.org/papers/capivasertib-plus-paclitaxel-versus-placebo-plus-paclitaxel-as-first-line/)
- [Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant](https://scholariq.org/papers/heterogeneity-and-clinical-significance-of-esr1-mutations-in-er-positive/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)
- [Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)](https://scholariq.org/papers/differential-regulation-of-pd-l1-expression-by-immune-and-tumor-cells-in-nsclc/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.